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Objective: To evaluate the resistance and mortality rates of multidrug-resistant tuberculosis (MDR-TB) in human 
immunodeficiency virus type 1 (HIV-1)-infected patients in a 1000-bed teaching hospital in inner-city Barcelona. 
Methods: A total of 311 patients, recruited between July 1991 and July 1993, had either tuberculosis (TB) with HIV 
(group A), TB without HIV (group B), or TB without HIV and previous exposure to antituberculosis drugs (group C). 
Mycobacterium tuberculosiswas isolated radiometrically or using Lowenstein-Jensen media with p-nitro-a-acetylamino- 
B-hidroxypropiphenone (NAP) testing. Antibiograms to isoniazid, rifampicin, pyrazinamide, ethambutol and 
streptomycin were performed by the critical proportions method with only one strain per patient. 
Results: Of 197 strains of M. tuberculosis isolated in group A, six (3%) were resistant to one agent and seven (3.5%) 
were multiresistant vs five (5.7%) and three (3.4%) of 88 strains, respectively, in group B, and three (11.5%) and seven 
(26.9%) of 26 strains, respectively, in group C. 
Conclusions: The primary resistance rate of M. tuberculosis in Spain remains relatively low in both HIV-infected and 
non-HIV-infected patients in contrast to a nearly 30% or higher resistance rate among patients previously exposed to 
antituberculosis agents. 
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During the last 5 years, an increase in the baseline 
percentage of multidrug-resistant tuberculosis (MDR- 
TB) has been reported in specific geographical areas 
of the US [l-41. In addition, several outbreaks of 
tuberculosis (TB) caused by such strains have also been 
described in the US and France. Most of these cases 
involved patients with nosocomially acquired human 
immunodeficiency virus (HIV) infections that could 
be traced to an index case [S-lo]. The mortality 
apparently associated with MDR-TB was as high as 
In Spain, a form of extrapulmonary or dis- 
seminated TB is the most frequent opportunistic 
80% [ll-131. 
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infection in HIV-infected patients and is the indicator 
event for acquired immunodeficiency syndrome 
(AIDS) in approximately 40% of cases [14]. In drug 
addicts (who represent around two-thirds of the HIV- 
infected population), the potential lack of compliance 
with antituberculosis treatment has not yet been 
associated with an increase in the prevalence of MDR- 
TB and no outbreaks have yet been reported. Thus, 
this prospective and descriptive study was devised to 
describe the prevalence and characteristics of MDR- 
TB in patients with and without HIV in Barcelona. 
PATIENTS 
Between July 1991 and July 1993, a total of31 1 patients 
were consecutively diagnosed to have TB and were 
either already known to have HIV or gave their 
permission to be tested for the presence of HIV 
infection. In all cases, the diagnosis of TB was based on 
the presence of clinically consistent data plus the 
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isolation and identification of Mycobacterium tubernrlosis 
in at least one sample. Patients were thus divided into 
three cohorts: group A, 197 consecutive HIV-infected 
patients; group B, 88 consecutive non-HIV-infected 
patients; and group C, 26 non-consecutive non-HIV- 
infected patients whose antibiograrm were specifically 
requested by the treating physician because of no 
response or possible resistance. 
METHODS 
Primary resistance was defined as resistance to one or 
more antituberculosis agents in patients without 
previous exposure to such agents, and MDR-TB was 
defined as resistance to at least two of the major 
antituberculosis agents. Primary isolation of the 
mycobacterial strains was carried out using either 
Lowenstein-Jensen slants or the 12B BACTEC 460 
radiometric TB system (Becton Diclunson Diagnostic 
Instrument Systems, Sparks, MD). Isolates were 
identified by a biochemical test using p-nitro-a- 
acetylamino-B-hidroxypropiphenone (NAP) in 
conjunction with the BACTEC system. 
Susceptibility tests were carried out, using the 
critical proportions method, on a range of anti- 
tuberculosis drugs including isoniazid, rifampicin, 
ethambutol and streptomycin (by the BACTEC 
system) and pyrazinamide (by a commercially prepared 
drug containing Lowenstein-Jensen medium; 
BioMerieux, Marcy-L'Etoile, France). The critical 
concentrations tested were: 200 mg/L for pyrazin- 
amide; 0.1 mg/L for isoniazid; 2 mg/L for rifampicin; 
7.5 mg/L for ethambutol; and 6 mg/L for strepto- 
mycin. Two strains of M. tuberculosis H37Rv - ATCC 
35822, which is resistant to isoniazid, and ATCC 
27294, which is susceptible to all antituberculosis 
agents - were used as reference strains for quality 
control and tested in parallel. 
Statistical analyses 
Proportions were compared by chi-square test with 
Yates correction or by Fisher's exact test as necessary. 
The odds ratio (OR) and 95% confidence intervals 
(CI) were calculated by the Epi Info program (version 
5.1 01B). All p values are two-tailed and considered 
significant if less than 0.05 [15,16]. 
Group A 
During the 2-year study period, resistance to a single 
agent was detected in six (3%) and resistance to two or 
more agents in seven (3.5%) HIV-infected patients. The 
resistance rate was 28.2% (1 1 out of 39) in patients who 
had been one to four times previously exposed to 
antituberculosis agents because of episodes of TB, 
relapses or apparent treatment failure, compared with 
1.3% (2 out of 158) in those not previously exposed 
( p < O . O O O l ;  OR = 30.6; 95% CI 6 to 291; Table 1). 
All 13 resistant patients were Spanish; 11 were drug 
addicts and 2 were homosexual. At the time that 
resistance was detected, nine had only pulmonary TB 
and four had an extrapulmonary localization. As all 11 
patients previously exposed to treatment were drug 
addicts, compliance was difficult to evaluate. Further- 
more, one also had a prior history of intolerance to 
several medications and another was in prison. Three 
(23%) of the 13 patients died during the episode in 
which resistance was detected. 
Table 1 Patterns of resistance in the three study patient groups 
Group 
A' B2 c3 
n % n % n % 
~ ~ 
Total (n) 197 88 26 
10 3 8 5  Resistant to at least one drug 13 6.5 
Resistant to one drug 6 3 5 5 7  3 11.5 
8 9.1 
Isoniazid 5 5 3 
kfarnpicin 1 0 0 
Isoniavd and rifampicm 1 2 5 
Isonmid, nfarnpicm and ethambutol 0 0 2 
Mulnresiscant 7 3 5  3 3 4  7 2 6 9  
Isomavd and ethambutol 6 1 0 
Primary resistance4 to at least one drug 2 1 4 4.5 1 3 8  
1 = consecunve HIV-infected patlents; 2 = COIlSeCuhVe non-HIV-mfected panents, 3 = non-consecuhve non-HIV-mfected panents tested 
on request of treanng physicians, 4 = panenu not prevlously exposed to antltuberculosis agents. 
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Group B 
In t h i s  group of 88 patients recruited from the 
metropolitan area of Barcelona, five (5.7%) had strains 
resistant to isoniazid and three (3.4%) were multi- 
resistant. The resistance rate was 26% (4 out of 15) in 
patients previously exposed to antituberculosis agents 
compared with 5.4% (4 out of 73) in those not 
previously exposed (p = 0.03; OR = 6.3; 95% CI 1 to 
38; Table 1). 
Thus, a total of 15 out of 21 patients (71.4%) with 
a resistant strain had been previously exposed to 
antituberculosis agents (11/13 in group A and 4/8 in 
group B). 
Group C 
Of these 26 non-consecutive HIV-seronegative patients 
tested for M. tuberculosis resistance by specific request of 
their treating physicians, three (1 1.5%) were resistant 
to isoniazid and seven (26.8%) were multiresistant, 
and nine (90%) of these 10 patients had been previously 
exposed to antituberculosis agents (Table 1). 
DISCUSSION 
Parts of the Western world appear to be experiencing 
a rise in resistance to M. tuberculosis in parallel with the 
increase in incidence of TB [17]. The most important 
predictor of MDR-TB is a previous history of anti- 
tuberculosis treatment (OR = 2.7) [4], and other risk 
factors are parenteral drug addiction and HIV infection 
[18-201. In some areas of the US, MDR-TB has 
acquired alarming proportions. In New York, for 
example, 33% of strains &om a cohort of 518 TB 
patients were resistant to at least one drug: 26% were 
resistant to isoniazid; 22% to rifampicin; and 19% to 
both isoniazid and rifampicin [4]. In 1991, a national 
SUNV in the US showed a 9.5% rate of resistance to 
both these drugs and a 3.5% rate of multiresistance, 
with the rate in New York (52.4%) being consider- 
ably higher than those in the other states [l]. One 
center in New York reported an increased prevalence 
of isoniazid and rifampicin resistance from 2.5% in 
1971 to 16% in 1991 predominantly in patients belong- 
ing to ethnic minorities or among the ranks of the 
unemployed, homeless, drug addicts or HIV-infected 
Several outbreaks of MDR-TB have been 
documented in New York, New Jersey and Florida, 
involving more than 200 patients, 80% of whom were 
coinfected with HIV-1 [22]. MDR-TB is associated 
with an increased rate of relapses, lack of response to 
treatment and mortality even in non-HIV-infected 
patients [23] whereas, in HIV-infected patients, the 
1211. 
crude m o r d t y  rate is > 70% with a median s u M d  of 
2.1 months [ll]. 
In contrast, a study carried out in England and 
Wales in 1982 and in 1991 resulted in resistance rates 
of 9.8% and 14.2%, respectively, to at least one agent; 
only 0.6% ofthe isolates were multiresistant strains [24]. 
The resistance rates were not higher among patients 
with HIV [25]. 
In our study, the overall prevalence of MDR-TB 
was relatively low. Among the HIV-infected (group A) 
patients, 3% were resistant to one drug and 3.5% were 
multiresistant vs 5.7% and 3.4%, respectively, in non- 
HIV-infected (group B) patients. However, resistance 
in patients previously exposed to antituberculosis treat- 
ment was nearly 30% with or without HIV infection. 
It is noteworthy that 71.4% of resistant strains were 
from patients previously exposed to treatment (84.4% 
in group A and 50% in group B). As expected, the 
overall percentage of resistant strains in group C was 
much higher than in either group A or B. 
These results are sirmlar to those reported by other 
workers in different geographical areas of Spain [26- 
281, which has favorable conditions for increases in 
both the baseline level of resistance to TB and the 
development of outbreaks of MDR-TB. Spain also has 
the highest cumulative incidence of AIDS in Europe, 
and the highest rates of coinfection with M. tuberculosis 
and HIV among developed countries [29]. Further- 
more, 70% of Spanish HIV-infected patients are drug 
addicts with potential problems of compliance with 
antituberculosis therapies. 
Both resistant and multiresistant strains have been 
detected in our study, and both were virulent in 
patients with HIV Thus, there is a potential for disease 
dissemination and an urgent requirement for institution 
of appropriate control measures, such as treatment 
under direct observation or in isolation, as well as other 
precautions in healthcare facilities. 
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